Taiwan
· Delayed Price · Currency is TWD Lin BioScience Statistics
Total Valuation
Lin BioScience has a market cap or net worth of TWD 7.30 billion. The enterprise value is 4.99 billion.
| Market Cap | 7.30B |
| Enterprise Value | 4.99B |
Important Dates
The next estimated earnings date is Wednesday, November 13, 2024.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Lin BioScience has 78.63 million shares outstanding. The number of shares has increased by 6.63% in one year.
| Shares Outstanding | 78.63M |
| Shares Change (YoY) | +6.63% |
| Shares Change (QoQ) | +3.94% |
| Owned by Insiders (%) | 1.85% |
| Owned by Institutions (%) | 0.12% |
| Float | 76.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 2.88 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.82 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.20 |
Financial Position
The company has a current ratio of 32.95, with a Debt / Equity ratio of 0.86.
| Current Ratio | 32.95 |
| Quick Ratio | 31.70 |
| Debt / Equity | 0.86 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.03 |
| Interest Coverage | -1,141.95 |
Financial Efficiency
Return on equity (ROE) is -37.51% and return on invested capital (ROIC) is -24.71%.
| Return on Equity (ROE) | -37.51% |
| Return on Assets (ROA) | -23.80% |
| Return on Capital (ROIC) | -24.71% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.20% in the last 52 weeks. The beta is -0.06, so Lin BioScience's price volatility has been lower than the market average.
| Beta (5Y) | -0.06 |
| 52-Week Price Change | -25.20% |
| 50-Day Moving Average | 99.17 |
| 200-Day Moving Average | 100.20 |
| Relative Strength Index (RSI) | 44.14 |
| Average Volume (20 Days) | 185,137 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -1.28B |
| Pretax Income | -1.22B |
| Net Income | -731.66M |
| EBITDA | -1.27B |
| EBIT | -1.28B |
| Earnings Per Share (EPS) | -9.49 |
Balance Sheet
The company has 4.17 billion in cash and 37.30 million in debt, giving a net cash position of 4.13 billion or 52.50 per share.
| Cash & Cash Equivalents | 4.17B |
| Total Debt | 37.30M |
| Net Cash | 4.13B |
| Net Cash Per Share | 52.50 |
| Equity (Book Value) | 4.35B |
| Book Value Per Share | 32.29 |
| Working Capital | 4.20B |
Cash Flow
In the last 12 months, operating cash flow was -1.18 billion and capital expenditures -5.49 million, giving a free cash flow of -1.19 billion.
| Operating Cash Flow | -1.18B |
| Capital Expenditures | -5.49M |
| Free Cash Flow | -1.19B |
| FCF Per Share | -15.12 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Lin BioScience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -6.63% |
| Shareholder Yield | -6.63% |
| Earnings Yield | -10.22% |
| FCF Yield | -16.28% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |